MiniValuatorMiniValuator
    估值工具
  • 股票估值
  • AI 分析New
  • 內容
  • 定價
MiniValuatorMiniValuator

極簡股票估值工具(DCF & PE),源自我們的投資社羣。

工具
DCF 計算器PE 計算器工具對比DCF 估值PE 估值定價
熱門股票
AAPL 股票估值MSFT 股票估值GOOGL 股票估值AMZN 股票估值TSLA 股票估值檢視全部
學習
DCF 方法論PE 方法論術語表使用指南投資洞察
核心概念
內在價值自由現金流WACC安全邊際終值市盈率
社羣
關於我們小紅書Newsletter
資源
llms.txtllms-full.txt
Built for value investors
© 2024 MiniValuator, All rights reserved
隱私政策服務條款
››AMGN

Amgen Inc. (AMGN) PE 估值

Drug Manufacturers - General · NASDAQ

当前价格

$348.77

内在价值

使用下方计算器估算

使用 PE 市盈率计算 AMGN 公允价值

对 Amgen Inc. 运行 PE 市盈率估值,自动填充盈利数据,可调节目标 PE,即时获得公允价值估算。

公司简介

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

财务指标 — AMGN PE 估值数据

Earnings Yield

4.10%

ROE (TTM)

96.7%

基于过去 12 个月的数据,AMGN 每股收益为 N/A,市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。

常见问题

AMGN 的市盈率是多少?

AMGN 的过去 12 个月市盈率反映投资者为 Amgen Inc. 每一美元收益所支付的价格。该指标在与Drug Manufacturers - General同类公司和公司自身历史区间对比时最有意义。

基于市盈率,AMGN 被高估了吗?

AMGN 是否被高估取决于将其市盈率与Drug Manufacturers - General同类公司、历史均值和增长预期比较。高于行业均值的 PE 可能暗示高估,但高增长公司通常有更高的估值倍数。建议配合 DCF 模型获得更完整的判断。

如何使用市盈率对 AMGN 进行估值?

对 Amgen Inc. 使用 PE 估值的步骤:(1) 将当前市盈率与Drug Manufacturers - General中位数对比评估相对定价,(2) 查看 PEG 比率以调整增长预期,(3) 参考 5 年 PE 历史区间判断当前位置,(4) 用目标 PE 乘以前瞻 EPS 估算公允价值。这种相对估值方法与 DCF 的绝对估值互为补充。

AMGN 的 PEG 比率是多少?

PEG 比率将市盈率除以预期盈利增速,提供增长调整后的估值指标。PEG 低于 1.0 可能表明相对于增长被低估,高于 2.0 可能暗示高估。PEG 对盈利增长稳定可预测的公司最为可靠。

对 AMGN 应该使用 PE 还是 DCF 估值?

PE 市盈率给出快速的相对定价——AMGN 相对于Drug Manufacturers - General同类的估值水平。DCF 基于预期自由现金流提供绝对价值。对于 AMGN,ROE 达到 96.7%,两种方法都值得使用——PE 做市场对比,DCF 验证基本面是否支撑当前价格。两种方法各有盲区:PE 忽略了资本结构和现金流质量,DCF 则对增长率和折现率假设非常敏感。

了解更多

  • AMGN AI 护城河与风险分析 → — AI 生成的竞争护城河与投资风险深度分析
  • 查看 AMGN DCF 估值 → — 通过折现现金流分析计算内在价值
  • PE 方法论 — PE 市盈率估值分步指南
  • DCF 方法论 — 折现现金流分析指南
  • PE 市盈率 — 理解市盈率
  • 内在价值 — 如何评估股票公允价值

相关 PE 估值

UNH查看 PEJNJ查看 PELLY查看 PEABBV查看 PEMRK查看 PETMO查看 PEABT查看 PEDHR查看 PE
PE 估值
Healthcare
打开 AMGN PE 计算器
或试试 AMGN DCF 估值 →